Cargando…
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Higher Education Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673315/ https://www.ncbi.nlm.nih.gov/pubmed/33210243 http://dx.doi.org/10.1007/s13238-020-00803-w |
| _version_ | 1783611294182539264 |
|---|---|
| author | Fu, Wenyu Chen, Yujianan Wang, Kaidi Hettinghouse, Aubryanna Hu, Wenhuo Wang, Jing-Quan Lei, Zi-Ning Chen, Zhe-Sheng Stapleford, Kenneth A. Liu, Chuan-ju |
| author_facet | Fu, Wenyu Chen, Yujianan Wang, Kaidi Hettinghouse, Aubryanna Hu, Wenhuo Wang, Jing-Quan Lei, Zi-Ning Chen, Zhe-Sheng Stapleford, Kenneth A. Liu, Chuan-ju |
| author_sort | Fu, Wenyu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7673315 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Higher Education Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76733152020-11-19 Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction Fu, Wenyu Chen, Yujianan Wang, Kaidi Hettinghouse, Aubryanna Hu, Wenhuo Wang, Jing-Quan Lei, Zi-Ning Chen, Zhe-Sheng Stapleford, Kenneth A. Liu, Chuan-ju Protein Cell Letter Higher Education Press 2020-11-18 2021-07 /pmc/articles/PMC7673315/ /pubmed/33210243 http://dx.doi.org/10.1007/s13238-020-00803-w Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Fu, Wenyu Chen, Yujianan Wang, Kaidi Hettinghouse, Aubryanna Hu, Wenhuo Wang, Jing-Quan Lei, Zi-Ning Chen, Zhe-Sheng Stapleford, Kenneth A. Liu, Chuan-ju Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title_full | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title_fullStr | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title_full_unstemmed | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title_short | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction |
| title_sort | repurposing fda-approved drugs for sars-cov-2 through an elisa-based screening for the inhibition of rbd/ace2 interaction |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673315/ https://www.ncbi.nlm.nih.gov/pubmed/33210243 http://dx.doi.org/10.1007/s13238-020-00803-w |
| work_keys_str_mv | AT fuwenyu repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT chenyujianan repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT wangkaidi repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT hettinghouseaubryanna repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT huwenhuo repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT wangjingquan repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT leizining repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT chenzhesheng repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT staplefordkennetha repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction AT liuchuanju repurposingfdaapproveddrugsforsarscov2throughanelisabasedscreeningfortheinhibitionofrbdace2interaction |